pharma slow waters-specif item balanc
portfolio strong confirm signal healthi
market guidanc assum larg us india pharma
recov pt
question remain in-lin investor question cours
regard focus impli back-half ramp pharma market share
trend india recoveri see management visit note india modestli
better share/mass spec remain open item hardwar revenu
remain neg pharma slower rel acceler industri
academ trend line think driver
balanc view quarter in-lin result though still
question back half achiev remain resolut view us
larg pharma india demand recov back half custom
quot trend end user demand pill count consum trend
robust view end-us demand resili call real
compani opportun take advantag pent-up demand
respond competit refocus sale forc visibl admittedli low
pt
result mean tool wat organ growth
trend last three year evid avail far
stack posit across larger sampl last week post
composit life sciences/diagnost growth cap best run sinc
prior cycl see quarter result around
space includ gxi point stabl improv trend pharma
specif specif outlier post
stack deceler pharma exhibit growth pharma
lightest vs group year acknowledg heighten
competit factor specif ms/pharma wat exposur pharma
 hardwar roughli sale detail exhibit compar
group outsid pharma wat ta strength good baromet
industri overal tool growth acceler stack
broad-bas strength view remain trend like solid
risk concentr china see preview academic/govern
strength standout surpris given strong nih trend
challeng read-through given posit narrow
life scienc tool diagnost unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
competit intens creat lumpi quarter
guidanc still impli back-half acceler guidanc year exhibit
unchang asid fx impact underli organ guidanc left
unchang constant currenc growth impli comp-
adjust acceler pharma expect reacceler note
recur revenu remain strong slow concentr larg pharma
biolog gener strong high-r mass spec d/discoveri
attribut acceler expect better trend india
product ramp new sale forc rep stronger us/large/india pharma
growth assumpt year-end budget flush guidanc
buy-back remain place note pace
buy-back commit number buy-back would impli
upsid guidanc model
detail quarter varianc trend insid exhibit china
remain strong mid-teen growth stack acceler
seen impact tariff date estim exposur modest
sale potenti expos tariff exhibit ii trend india
improv sale pharma thaw pent-up demand build growth
acceler stack comp easier given gst impact
began iii mass spec improv sequenti still light high-r
mass spec sale ms challeng iv say continu
develop comprehens program look cost drive effici
busi organ ebit margin expand ex-fx/mix mark
consecut quarter organ margin expans see unmet
technolog need plan introduc better ms interfac
satisfi demand larg food materi lab china/europ
lower organ growth fx estim pt lower organ
growth estim reflect caution
india/pharma trend maintain margin assumpt overal
lower ep lower pt base yield
mid estim higher yield reflect slower
thomson reuter morgan stanley research
deriv base-cas scenario
bull case ep
bull case ep
competit posit macro stronger expect lead
sustain top-line growth ebit margin expans cost
program price robust anticip pharma momentum
remain stronger longer expect gain market share
industrial/academ market drive upsid multipl expand
earn current level peak level
base ep
base ep
pharma momentum drive organ growth share loss
moder acceler academ market support top-lin
organ margin expand ex fx/mix cost program gener
save price power increas pt reflect yield
mid estim impli ep current level
pt emb expect substanti capit deploy ep benefit
bear ep
bear ep
pharma academ growth challeng market share loss greater
expect lead top-line growth program fail gain
traction price come pressur lead ebit margin declin
multipl contract ten-year averag
direct beneficiari
momentum pharma market tool
stronger share pharma market trend
support case stronger top line growth
opportun still appear limit
compar peer think peer
averag organ margin
expans next two year vs
closer see upsid
estim robust oper
improv initi
knowledg dollar amount expect
save program given
modest margin expans outlook expect
ep growth remain modest rel
peer vs tool averag
china exposur concentr pharma
market remain strong
risk achiev price
market deceler tough comp
posit less defens expect
share loss increas iii oper
leverag weaker expect cost
program fail gain traction price
market acceler stronger
budget ii competit posit
defens expect iii oper
leverag higher expect
robust cost program price power
flat due ms specif high-r lc stronger growth challeng biomed research
y/i discoveri strong
organ dd growth china off-set declin develop market driven slower budget releas
larg pharma custom growth larg molecul busi
organ ta continu strong thermal rheolog strong softer food/env stronger
us y/i weak biomed research slower pharma growth
industri govern strong pharma softer due comp
exhibit estim organ growth
accel sale
comp-adjust acceler academ deceler pharma/industri
channel improv given us/eu budget acceler deceler tough comp
survey suggest budget acceler deceler tough comp
strength coincid indic deceler lead indic point
deceler late
acquisit sell day
acquisit sell day
exhibit estim tariff exposur sale
made
us
sold
made
sold
us
sale
exhibit highest india sale exposur tool
guidanc
fx sale
sale growth
sale growth
guidanc
fx sale
exhibit chang forecast
sale
sale
sale
sale
sale
sale
million except ep
acq sell day
approv brazil
compani data morgan stanley research
valuat risk
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
price target base yield mid
estim base upon organ growth ebit margin expans
impli ep multipl direct beneficiari
momentum pharma market tool yet see cours compani
grow ep faster larg cap peer group compani optim oper
focu pharma driver compani reason
compani unlik abl maintain multipl time despit
superior product line-up custom tie
downsid risk price target includ pharma end-market deceler tough
comp fade replac cycl ii competit posit less defens
expect share loss increas iii oper leverag weaker expect
cost program fail gain traction price power moder upsid risk includ
pharma end-market acceler stronger budget ii competit posit
defens expect iii oper leverag higher expect
robust cost program price power
total good sold
total chemisti consum
